Hui Y N, Meinert H, Arnold G, Kirchhof B, Walter P, Menz D H, Heimann K
Eye Center, Xijing Hospital, 4th Military Medical University, Xian, PR China.
Graefes Arch Clin Exp Ophthalmol. 1998 Sep;236(9):709-12. doi: 10.1007/s004170050145.
Using perfluoromethylcyclopentane (FMCP; US patent no. 5,441,989, granted 1995) we have developed a new vitreous gas tamponade in a rabbit model that allows complete filling of the vitreous cavity without vitrectomy and without a significant increase in intraocular pressure. In humans this procedure would allow the blockage of inferior and posterior retinal holes without special positioning of the patient. Perfluoromethylcyclopentane (FMCP), a liquid perfluorocarbon with a boiling point slightly above body temperature, is injected in minute volumes into the vitreous cavity, where it vaporizes, thereby filling a gas volume approximately 500 times its liquid volume. FMCP was injected into the midvitreous in six rabbits (six eyes). After 2-3 days a complete gas tamponade was achieved in three eyes. Two eyes showed 75-90% filling, and one eye was filled only 50% with gas. Intraocular pressure was highest in the completely filled eyes, ranging from 26.6 to 38.8 mmHg. In all eyes the maximum expansion of the gas bubble lasted 2 weeks. One eye developed a retinal detachment. All eyes showed transient subcapsular cataracts. The results of this study showed that intravitreal injection of FMCP, a new perfluorocarbon liquid, results in a complete gas tamponade of the vitreous cavity which lasts 2 weeks without severe intraocular pressure rise and without vitrectomy. This procedure will be especially useful for eyes that have retinal detachment from inferior or posterior retinal holes. Injection of a conventional gas such as SF6 or C3F8 usually does not block retinal holes in inferior or posterior locations without tedious positioning and risk of (transient) glaucoma. Since the mechanism of transition of FMCP from liquid to gas in the vitreous is poorly understood, we are currently studying FMCP vaporization in an in vitro eye model.
我们使用全氟甲基环戊烷（FMCP；美国专利号5,441,989，1995年授予）在兔模型中开发了一种新型玻璃体气体填塞物，该填塞物无需玻璃体切除术即可完全填充玻璃体腔，且不会显著增加眼压。在人类中，此 procedure 将允许在患者无需特殊体位的情况下封闭下方和后部视网膜裂孔。全氟甲基环戊烷（FMCP）是一种沸点略高于体温的液态全氟化碳，以微量注入玻璃体腔，在其中汽化，从而填充约为其液体体积500倍的气体体积。将FMCP注入6只兔（6只眼）的玻璃体中部。2至3天后，3只眼实现了完全气体填塞。2只眼显示填充率为75%至90%，1只眼仅填充了50%的气体。眼压在完全填充的眼中最高，范围为26.6至38.8 mmHg。在所有眼中，气泡的最大膨胀持续2周。1只眼发生了视网膜脱离。所有眼均出现了短暂的晶状体后囊下白内障。本研究结果表明，玻璃体内注射新型全氟化碳液体FMCP可导致玻璃体腔完全气体填塞，持续2周，且不会导致严重眼压升高，也无需玻璃体切除术。此 procedure 对于因下方或后部视网膜裂孔导致视网膜脱离的眼睛尤其有用。注射诸如SF6或C3F8等传统气体通常在没有繁琐体位且无（短暂）青光眼风险的情况下无法封闭下方或后部位置的视网膜裂孔。由于FMCP在玻璃体内从液体转变为气体的机制尚不清楚，我们目前正在体外眼模型中研究FMCP的汽化情况。
